textochbilcontainer
A BUSINESS MODEL WITH FASTER TIME TO MARKET AND LOWER DEVELOPMENT RISK COMPARED WITH CONVENTIONAL DRUG DEVELOPMENT
textochbilcontainer
RESULTS FROM THE TWO PHASE 3 STUDIES SHOW THAT MOB-015 HAS UNIQUE ANTIFUNGAL EFFECT
textochbilcontainer
Moberg pharma intends to submit a registration application in Europe in 2021.
textochbilcontainer
We support Barncancerfonden
Moberg Pharma is a rapidly growing Swedish pharmaceutical company commercializing proprietary, acquired and licensed products in the global market. Initially, the company specialized in the treatment of skin diseases, with a focus on treatments for nail fungus.
Stockvalue
- All pressreleases
- Regulatory
2021-12-23 | Press release
2021-12-06 | Press release
2021-11-09 | Press release
2021-12-23 | Press release
2021-12-06 | Press release
2021-11-09 | Press release
